Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: Initial experience with downsizing to reconsider cytoreductive surgery

World Journal of Urology

Volumn 27, Issue 4, 2009, Pages 533-539

  Bex, Axel ^a   van der Veldt, Astrid A M ^c   Blank, Christian ^b   van den Eertwegh, Alfons J M ^c   Boven, Epie ^c   Horenblas, Simon ^a   Haanen, John ^b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Nephrectomy; Primary tumour; Renal cell cancer; Sunitinib

Indexed keywords

ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; SUNITINIB;

ADJUVANT THERAPY; AGED; ARTICLE; FEMALE; HUMAN; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEPHRECTOMY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INDOLES; KAPLAN-MEIERS ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEPHRECTOMY; PYRROLES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 68549091054     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-008-0368-7     Document Type: Article

References (26)

1. Motzer RJ, Bukowski RM (2006) Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 24:5601-5608. doi: 10.1200/JCO.2006.08.5415
2. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124. doi: 10.1056/NEJMoa065044
3. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Bex A, de Gast GC, Haanen J, Boven E (2008) Sunitinib for treatment of advanced renal cell cancer: Primary tumor response. Clin Cancer Res 14:2431-2436. doi: 10.1158/1078-0432.CCR-07-4089
4. Bex A, Kerst M, Mallo H, Meinhardt W, Horenblas S, de Gast GC (2006) Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: A consecutive study. Eur Urol 49:76-81. doi: 10.1016/j.eururo.2005.09.011
5. Shuch B, Riggs SB, LaRochelle JC, Kabbinavar FF, Avakian R, Pantuck AJ, Patard JJ, Belldegrun AS (2008) Neoadjuvant targeted therapy and advanced kidney cancer: Observations and implications for a new treatment paradigm. BJU Int 102:692-696
6. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289-296. doi: 10.1200/JCO.20.1.289
7. Houk BE, Bello CL, Michaelson MD, Bukowski RM, Redman BG, Hudes GR, Wilding G, Motzer RJ (2007) Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): A population pharmacokinetic/ pharmacodynamic (PKPD) approach. J Clin Oncol 25:5027 (Meeting abstracts)
8. Chow LQM, Eckhardt SG (2007) Sunitinib: From rationale design to clinical efficacy. J Clin Oncol 25:884-896. doi: 10.1200/JCO.2006.06.3602
9. Mancuso M, Davis R, Norberg S, O'Brien S, Sennino B, Nakahara T, Yao V, Inai T, Brooks P, Freimark B, Shalinsky D, Hu-Lowe D, McDonald D (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116:2610-2621. doi: 10.1172/JCI24612
10. Jain R, Tong R, Munn L (2007) Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: Insights from a mathematical model. Cancer Res 67:2729-2735. doi: 10.1158/0008-5472.CAN-06-4102
11. Beisland C, Medby PC, Sander S, Beisland HO (2000) Nephrectomy - indications, complications and postoperative mortality in 646 consecutive patients. Eur Urol 37:58-64. doi: 10.1159/000020101
12. Wood CG (2007) Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: Combining surgery and systemic therapies to improve patient outcome. Clin Cancer Res 13:697s-702s. doi: 10.1158/1078-0432.CCR-06-2109
13. Kassouf W, Sanchez-Ortiz R, Tamboli P, Jonasch E, Merchant MM, Spiess PE, Wood CG (2007) Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: The M.D. Anderson Cancer Center experience. Urology 69:835-838. doi: 10.1016/j.urology.2007.01.034
14. Moul JW, Foley JP, Wind GG, Rubin S, Coffey JA, McLeod DG (1991) Celiac axis and superior mesenteric artery injury associated with left radical nephrectomy for locally advanced renal cell carcinoma. J Urol 164:1104-1107
15. Kelly R, Skinner D, Yellin AE, Weaver FA (1995) En bloc aortic resection for bulky metastatic germ cell tumors. J Urol 153:1849-1851. doi: 10.1016/S0022-5347(01)67328-2
16. Spitz A, Wilson TG, Kawachi MH, Ahlering TE, Skinner DG (1997) Vena caval resection for bulky metastatic germ cell tumors: An 18 year experience. J Urol 158:1813-1818. doi: 10.1016/S0022-5347(01)64137-5
17. Sawczuk IS, Pollard JC (1999) Renal cell carcinoma: Should radical nephrectomy be performed in the presence of metastatic disease? Curr Opin Urol 9:377-381. doi: 10.1097/00042307-199909000-00002
18. Sengupta S, Leibovich BC, Blute ML, Zincke H (2005) Surgery for metastatic renal cell cancer. World J Urol 23:155-160. doi: 10.1007/ s00345-005-0504-6
19. Yonover PM, Flanigan RC (2000) Should radical nephrectomy be performed in the face of surgically incurable disease? Curr Opin Urol 10:429-434. doi: 10.1097/00042307-200009000-00011
20. Pierorazio PM, McKiernan JM, McCann TR, Mohile S, Petrylak D, Benson MC (2007) Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed. BJU Int 100:755-759. doi: 10.1111/j.1464-410X.2007.07108.x
21. Reznek RH (1996) Imaging in the staging of renal cell carcinoma. Eur Radiol 6:120-128
22. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Charnsangavej C (2007) We should desist using RECIST, at least in GIST. J Clin Oncol 25:1760-1764. doi: 10.1200/JCO.2006.07.3411
23. Karakiewicz PI, Suardi N, Jeldres C, Audet P, Ghosn P, Patard JJ, Perrotte P (2007) Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol 53:845-848
24. Pantuck AJ, Belldegrun AS, Figlin RA (2007) Cytoreductive nephrectomy for metastatic renal cell carcinoma: Is it still imperative in the era of targeted therapy? Clin Cancer Res 13:693s-696s. doi: 10.1158/ 1078-0432.CCR-06-1916
25. Flanigan RC, Mickisch G, Sylvester R, Tangen C, van Poppel H, Crawford ED (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis. J Urol 171:1071-1076. doi: 10.1097/ 01.ju.0000110610.61545.ae
26. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: A randomised trial. Lancet 358:966-970. doi: 10.1016/S0140-6736(01)06103-7